Pub Date : 2025-05-09DOI: 10.1016/j.recesp.2025.04.008
Juan Manuel Serrano-Marcos , Víctor Manuel López-Espinosa , Míriam Cantero-Campos
{"title":"Afectación cardiaca poco común en osteosarcoma metastásico","authors":"Juan Manuel Serrano-Marcos , Víctor Manuel López-Espinosa , Míriam Cantero-Campos","doi":"10.1016/j.recesp.2025.04.008","DOIUrl":"10.1016/j.recesp.2025.04.008","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 12","pages":"Pages 1130-1131"},"PeriodicalIF":5.9,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-05DOI: 10.1016/j.recesp.2025.04.010
Francisco González-Vílchez , Luis Almenar-Bonet , Manuel Gómez-Bueno , María G. Crespo-Leiro , Manuel Cobo-Belaustegui , Manuel Crespín-Crespín , Carlos Ortiz-Bautista , Juan F. Delgado-Jiménez , Marta de Antonio-Ferrer , José Manuel Sobrino-Márquez , en representación de los Equipos Españoles de Trasplante Cardiaco , Miguel Llano-Cardenal , José Antonio Vázquez de Prada , Francisco Nistal-Herrera , Cristina Castrillo , Beatriz Díaz-Molina , Vanesa Alonso-Fernández , Cristina Fidalgo-Muñiz , Diego Rangel-Sousa , Antonio Grande-Trillo , Ferrán Gran-Ipiña
Introduction and objectives
This report presents updated data on heart transplants in Spain, including procedures carried out in 2024. It reviews trends over the past decade (2015-2024) in donor and recipient characteristics, surgical techniques, immunosuppression strategies, and survival rates.
Methods
Data were drawn from the Spanish heart transplant registry, which is updated annually. The analysis includes 347 transplants performed in 2024, as well as procedures from 2015 to 2023 (n = 2721).
Results
In 2024, the number of heart transplants increased by 6.8% compared with 2023. There were no significant changes in recipient age or sex, but the proportion of urgent transplants rose to 47.0%. Use of circulatory support devices increased, particularly extracorporeal membrane oxygenation. The average donor age showed a slight increase in 2024, although the long-term trend remained downward. Donation after circulatory death accounted for 29.1% of transplants in 2024. One-year survival rates improved, reaching 85.2% for transplants performed between 2021 and 2023.
Conclusions
The number of heart transplants continued to grow, nearing historic highs, largely due to the expansion of donation after circulatory death. Improved 1-year survival reflects the maturity of transplant programs, advances in surgical and medical management, and better pretransplant conditions in recipients.
{"title":"Registro español de trasplante cardiaco. XXXVI informe oficial de la Asociación de Insuficiencia Cardiaca de la Sociedad Española de Cardiología","authors":"Francisco González-Vílchez , Luis Almenar-Bonet , Manuel Gómez-Bueno , María G. Crespo-Leiro , Manuel Cobo-Belaustegui , Manuel Crespín-Crespín , Carlos Ortiz-Bautista , Juan F. Delgado-Jiménez , Marta de Antonio-Ferrer , José Manuel Sobrino-Márquez , en representación de los Equipos Españoles de Trasplante Cardiaco , Miguel Llano-Cardenal , José Antonio Vázquez de Prada , Francisco Nistal-Herrera , Cristina Castrillo , Beatriz Díaz-Molina , Vanesa Alonso-Fernández , Cristina Fidalgo-Muñiz , Diego Rangel-Sousa , Antonio Grande-Trillo , Ferrán Gran-Ipiña","doi":"10.1016/j.recesp.2025.04.010","DOIUrl":"10.1016/j.recesp.2025.04.010","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>This report presents updated data on heart transplants in Spain, including procedures carried out in 2024. It reviews trends over the past decade (2015-2024) in donor and recipient characteristics, surgical techniques, immunosuppression strategies, and survival rates.</div></div><div><h3>Methods</h3><div>Data were drawn from the Spanish heart transplant registry, which is updated annually. The analysis includes 347 transplants performed in 2024, as well as procedures from 2015 to 2023 (n<!--> <!-->=<!--> <!-->2721).</div></div><div><h3>Results</h3><div>In 2024, the number of heart transplants increased by 6.8% compared with 2023. There were no significant changes in recipient age or sex, but the proportion of urgent transplants rose to 47.0%. Use of circulatory support devices increased, particularly extracorporeal membrane oxygenation. The average donor age showed a slight increase in 2024, although the long-term trend remained downward. Donation after circulatory death accounted for 29.1% of transplants in 2024. One-year survival rates improved, reaching 85.2% for transplants performed between 2021 and 2023.</div></div><div><h3>Conclusions</h3><div>The number of heart transplants continued to grow, nearing historic highs, largely due to the expansion of donation after circulatory death. Improved 1-year survival reflects the maturity of transplant programs, advances in surgical and medical management, and better pretransplant conditions in recipients.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 10","pages":"Pages 906-915"},"PeriodicalIF":5.9,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-05DOI: 10.1016/j.recesp.2025.02.015
Raymond N. Haddad , Ali Houeijeh , Ender Odemis , Jean-Benoit Thambo , Turkay Saritas , Ibrahim Ece , Clement Karsenty , Kaan Yildiz , Mete Han Kizilkaya , Sébastien Hascoet , Hojat Mortezaeian , Harun Terin , Mohammed Kasem , Zakhia Saliba , Nazmi Narin
Introduction and objectives
The Lifetech KONAR-MF ventricular septal defect occluder (MFO) is increasingly used for transcatheter perimembranous ventricular septal defect (pmVSD) closure. We aim to collect real-world data on patient outcomes and MFO performance in pmVSD cases.
Methods
This was a nonrandomized, retrospective, multicenter, postmarketing clinical follow-up study of pmVSD patients implanted with the MFO device between 2018 and 2023. The primary endpoint was 6-month composite clinical success, defined as technical success (successful implantation and device retention at the end of the procedure), closure success (trivial or no residual shunt), absence of serious adverse events at 30 days, and no device removal or reintervention. Secondary endpoints consisted of technical success, procedural success (technical success and less than moderate residual shunt), closure success (clinically insignificant or absent residual shunt), and safety.
Results
Our cohort comprised 333 patients (51.4% male, 10.2% adults), with a median age of 4.6 [IQR, 2-10] years and a median weight of 17 [IQR, 11-32] kg. Baseline defect characteristics consisted of a left ventricular defect diameter of 8 [IQR, 7-10] mm, with 13.8% of patients having aortic valve regurgitation, 9.9% having an indirect Gerbode shunt, 10.5% having mild aortic valve prolapse, and 32.2% having subaortic rim deficiency. Closure via a retrograde approach was performed in 183 patients (55%). Technical success at procedure completion was 97.6%, and procedural success was 94.6%. Closure success at 6 months was 97.1%, while composite clinical success was 90.1%. Freedom from serious adverse events was 95.2% at 30 days. Freedom from device-related events was 96.8% at 6 months and 93.8% at 24 months. Risk factors for 6-month composite clinical failure were aortic valve prolapse (OR, 4.85; 95%CI, 2.07-11.39) and right ventricular defect diameter (OR, 1.41; 95%CI, 1.01-1.98).
Conclusions
Transcatheter closure of pmVSD with the MFO device demonstrated feasibility, effectiveness, and safety in real-world settings.
{"title":"MIOS-MFO, un estudio observacional internacional multicéntrico del oclusor KONAR-MF de Lifetech en el tratamiento de defectos septales ventriculares perimembranosos","authors":"Raymond N. Haddad , Ali Houeijeh , Ender Odemis , Jean-Benoit Thambo , Turkay Saritas , Ibrahim Ece , Clement Karsenty , Kaan Yildiz , Mete Han Kizilkaya , Sébastien Hascoet , Hojat Mortezaeian , Harun Terin , Mohammed Kasem , Zakhia Saliba , Nazmi Narin","doi":"10.1016/j.recesp.2025.02.015","DOIUrl":"10.1016/j.recesp.2025.02.015","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The Lifetech KONAR-MF ventricular septal defect occluder (MFO) is increasingly used for transcatheter perimembranous ventricular septal defect (pmVSD) closure. We aim to collect real-world data on patient outcomes and MFO performance in pmVSD cases.</div></div><div><h3>Methods</h3><div>This was a nonrandomized, retrospective, multicenter, postmarketing clinical follow-up study of pmVSD patients implanted with the MFO device between 2018 and 2023. The primary endpoint was 6-month composite clinical success, defined as technical success (successful implantation and device retention at the end of the procedure), closure success (trivial or no residual shunt), absence of serious adverse events at 30 days, and no device removal or reintervention. Secondary endpoints consisted of technical success, procedural success (technical success and less than moderate residual shunt), closure success (clinically insignificant or absent residual shunt), and safety.</div></div><div><h3>Results</h3><div>Our cohort comprised 333 patients (51.4% male, 10.2% adults), with a median age of 4.6 [IQR, 2-10] years and a median weight of 17 [IQR, 11-32] kg. Baseline defect characteristics consisted of a left ventricular defect diameter of 8 [IQR, 7-10] mm, with 13.8% of patients having aortic valve regurgitation, 9.9% having an indirect Gerbode shunt, 10.5% having mild aortic valve prolapse, and 32.2% having subaortic rim deficiency. Closure via a retrograde approach was performed in 183 patients (55%). Technical success at procedure completion was 97.6%, and procedural success was 94.6%. Closure success at 6 months was 97.1%, while composite clinical success was 90.1%. Freedom from serious adverse events was 95.2% at 30 days. Freedom from device-related events was 96.8% at 6 months and 93.8% at 24 months. Risk factors for 6-month composite clinical failure were aortic valve prolapse (OR, 4.85; 95%<span>C</span>I, 2.07-11.39) and right ventricular defect diameter (OR, 1.41; 95%CI, 1.01-1.98).</div></div><div><h3>Conclusions</h3><div>Transcatheter closure of pmVSD with the MFO device demonstrated feasibility, effectiveness, and safety in real-world settings.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 11","pages":"Pages 947-956"},"PeriodicalIF":5.9,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-05DOI: 10.1016/j.recesp.2025.04.005
Álvaro Montes Muñiz , Alberto Cecconi , Luis Jesús Jiménez-Borreguero
{"title":"Afinando en la valoración del exceso de trabeculación del ventrículo izquierdo","authors":"Álvaro Montes Muñiz , Alberto Cecconi , Luis Jesús Jiménez-Borreguero","doi":"10.1016/j.recesp.2025.04.005","DOIUrl":"10.1016/j.recesp.2025.04.005","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 11","pages":"Pages 945-946"},"PeriodicalIF":5.9,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-05DOI: 10.1016/j.recesp.2025.02.016
Andrea Zito , Francesco Burzotta , Cristina Aurigemma , Enrico Romagnoli , Francesco Bianchini , Emiliano Bianchini , Lazzaro Paraggio , Mattia Lunardi , Carolina Ierardi , Filippo Crea , Antonio Maria Leone , Carlo Trani
Introduction and objectives
The management of patients with coronary artery disease can benefit from devices that improve functional or anatomical evaluation. This study aimed to compare the efficacy of optical coherence tomography (OCT) and fractional flow reserve (FFR) guidance for managing vessels with angiographically intermediate coronary lesions according to angiographic lesion complexity.
Methods
The FORZA trial (NCT01824030) was a randomized trial comparing the use of OCT or FFR for revascularization decisions and percutaneous coronary intervention optimization in patients with angiographically intermediate coronary lesions. Complex lesions were defined as long (length > 38 mm), severely calcified, or bifurcation lesions. The primary outcome was major adverse cardiac events (MACE), defined as a composite of all-cause death, myocardial infarction, or target vessel revascularization.
Results
A total of 420 vessels (200 OCT-guided and 220 FFR-guided) were enrolled, including 212 vessels with complex lesions. At the 5-year follow-up, the MACE rate was 20.8% in vessels with complex lesions and 13.9% in vessels with noncomplex lesions (HR, 1.52; 95%CI, 0.95-2.44; P = .078). Compared with FFR, OCT was associated with a lower risk of MACE in vessels with complex lesions (HR, 0.53; 95%CI, 0.28-0.98; P = .044), but with a higher risk of MACE in vessels with noncomplex lesions (HR, 2.23; 95%CI, 1.04-4.81; P = .040; Pinteraction = .004).
Conclusions
In vessels with angiographically intermediate coronary lesions, angiographic lesion complexity may modulate the long-term efficacy of the guidance modality, with a potential benefit of OCT in complex lesions and FFR in noncomplex lesions.
介绍和目的冠状动脉疾病患者的治疗可以从改善功能或解剖评价的器械中获益。本研究旨在比较光学相干断层扫描（OCT）和分数血流储备（FFR）指导根据血管造影病变复杂性对冠脉造影中期病变血管的治疗效果。方法FORZA试验（NCT01824030）是一项随机试验，比较使用OCT或FFR进行血管重建决策和经皮冠状动脉介入治疗对血管造影中期冠状动脉病变患者的影响。复杂病变被定义为长（长度>； 38mm），严重钙化或分叉病变。主要终点是主要心脏不良事件（MACE），定义为全因死亡、心肌梗死或靶血管重建术的综合结果。结果共纳入420条血管（oct引导200条，ffr引导220条），其中病变复杂的血管212条。在5年随访中，复杂病变血管的MACE率为20.8%，非复杂病变血管的MACE率为13.9% （HR, 1.52; 95%CI, 0.95-2.44; P = 0.078）。与FFR相比，OCT与复杂病变血管发生MACE的风险较低（HR, 0.53; 95%CI, 0.28-0.98; P = 0.044），但与非复杂病变血管发生MACE的风险较高（HR, 2.23; 95%CI, 1.04-4.81; P = 0.040； P相互作用= 0.004）。结论在冠状动脉造影中度病变的血管中，血管造影病变复杂性可能调节引导方式的长期疗效，在复杂病变中OCT和非复杂病变中FFR具有潜在的优势。
{"title":"Reserva fraccional de flujo u OCT para guiar el tratamiento de estenosis coronarias complejas y no complejas angiográficamente intermedias","authors":"Andrea Zito , Francesco Burzotta , Cristina Aurigemma , Enrico Romagnoli , Francesco Bianchini , Emiliano Bianchini , Lazzaro Paraggio , Mattia Lunardi , Carolina Ierardi , Filippo Crea , Antonio Maria Leone , Carlo Trani","doi":"10.1016/j.recesp.2025.02.016","DOIUrl":"10.1016/j.recesp.2025.02.016","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The management of patients with coronary artery disease can benefit from devices that improve functional or anatomical evaluation. This study aimed to compare the efficacy of optical coherence tomography (OCT) and fractional flow reserve (FFR) guidance for managing vessels with angiographically intermediate coronary lesions according to angiographic lesion complexity.</div></div><div><h3>Methods</h3><div>The FORZA trial (<span><span>NCT01824030</span><svg><path></path></svg></span>) was a randomized trial comparing the use of OCT or FFR for revascularization decisions and percutaneous coronary intervention optimization in patients with angiographically intermediate coronary lesions. Complex lesions were defined as long (length ><!--> <!-->38<!--> <!-->mm), severely calcified, or bifurcation lesions. The primary outcome was major adverse cardiac events (MACE), defined as a composite of all-cause death, myocardial infarction, or target vessel revascularization.</div></div><div><h3>Results</h3><div>A total of 420 vessels (200 OCT-guided and 220 FFR-guided) were enrolled, including 212 vessels with complex lesions. At the 5-year follow-up, the MACE rate was 20.8% in vessels with complex lesions and 13.9% in vessels with noncomplex lesions (HR, 1.52; 95%<span>C</span>I, 0.95-2.44; <em>P</em> <!-->=<!--> <!-->.078). Compared with FFR, OCT was associated with a lower risk of MACE in vessels with complex lesions (HR, 0.53; 95%CI, 0.28-0.98; <em>P</em> <!-->=<!--> <!-->.044), but with a higher risk of MACE in vessels with noncomplex lesions (HR, 2.23; 95%CI, 1.04-4.81; <em>P</em> <!-->=<!--> <!-->.040; <em>P</em><sub>interaction</sub> <!-->=<!--> <!-->.004).</div></div><div><h3>Conclusions</h3><div>In vessels with angiographically intermediate coronary lesions, angiographic lesion complexity may modulate the long-term efficacy of the guidance modality, with a potential benefit of OCT in complex lesions and FFR in noncomplex lesions.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 10","pages":"Pages 876-885"},"PeriodicalIF":5.9,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-26DOI: 10.1016/j.recesp.2024.12.014
Hugues Lucron , Sophie-Guiti Malekzadeh-Milani , Thomas Perouse de Montclos , Alban-Elouen Baruteau , Alberto Mendoza Soto , Gianfranco Butera , Ina Michel-Behnke , Caroline Ovaert , Carles Bautista-Rodriguez , James Bentham , Zakaria Jalal , Pedro Betrian Blasco , Hélène Bouvaist , Marie Vincenti , José Diego Ferreira Matins , Jean-Marc Jellimann , Alessia Callegari , Laurent Bonnemains , Ronan Bonnefoy , Biagio Castaldi , Damien Bonnet
Introduction and objectives
Balloon atrial septostomy (BAS) improves oxygenation in neonates with transposition of the great arteries (TGA) and restrictive foramen ovale. Currently, there is a global shortage of dedicated BAS catheters, while new unmarked catheters have recently become available at some European centers. This study aimed to characterize BAS outcomes using the currently available BAS catheters in Europe.
Methods
A 2-year multicenter observational registry was conducted, including all neonates undergoing BAS for TGA. We report preliminary results (September 2022-February 2024) focusing on BAS characteristics and outcomes.
Results
A total of 250 BAS procedures were performed in 29 centers. The median neonatal weight was 3.16 kg, and 88% of neonates had a prenatal diagnosis. Most procedures were performed often on the first day of life during working hours (72.8%), mainly in catheterization laboratories (59.2%). Guidance primarily involved ultrasound with or without fluoroscopy. A guidewire was used in 41.2% of procedures. A total of 290 catheters (286 Z-5 or Z-6) were used, achieving an overall BAS success rate of 96%. Complete procedural failure was associated with the use of the umbilical venous route (OR, 3.62; P = .001) and lower-volume catheters (OR, 7.01; P < .001). The occurrence of significant complications (8%; OR, 9.33; P < .001) was associated with complete procedural failure. For complex procedures, significant risk factors were the absence of fluoroscopy (OR, 3.32; P = .001), use of the umbilical venous route (OR, 2.28; P = .005), and lower-volume catheters (OR, 2.43; P = .03).
Conclusions
In the current era, BAS can be challenging, and significant complications and complete failures are not uncommon. The use of the umbilical venous route, low-volume BAS catheters, absence of fluoroscopy guidance, and the occurrence of complications negatively impact procedural outcomes.
{"title":"Atrioseptostomía con balón para la transposición de las grandes arterias en Europa: características y resultados actuales","authors":"Hugues Lucron , Sophie-Guiti Malekzadeh-Milani , Thomas Perouse de Montclos , Alban-Elouen Baruteau , Alberto Mendoza Soto , Gianfranco Butera , Ina Michel-Behnke , Caroline Ovaert , Carles Bautista-Rodriguez , James Bentham , Zakaria Jalal , Pedro Betrian Blasco , Hélène Bouvaist , Marie Vincenti , José Diego Ferreira Matins , Jean-Marc Jellimann , Alessia Callegari , Laurent Bonnemains , Ronan Bonnefoy , Biagio Castaldi , Damien Bonnet","doi":"10.1016/j.recesp.2024.12.014","DOIUrl":"10.1016/j.recesp.2024.12.014","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Balloon atrial septostomy (BAS) improves oxygenation in neonates with transposition of the great arteries (TGA) and restrictive foramen ovale. Currently, there is a global shortage of dedicated BAS catheters, while new unmarked catheters have recently become available at some European centers. This study aimed to characterize BAS outcomes using the currently available BAS catheters in Europe.</div></div><div><h3>Methods</h3><div>A 2-year multicenter observational registry was conducted, including all neonates undergoing BAS for TGA. We report preliminary results (September 2022-February 2024) focusing on BAS characteristics and outcomes.</div></div><div><h3>Results</h3><div>A total of 250 BAS procedures were performed in 29 centers. The median neonatal weight was 3.16<!--> <!-->kg, and 88% of neonates had a prenatal diagnosis. Most procedures were performed often on the first day of life during working hours (72.8%), mainly in catheterization laboratories (59.2%). Guidance primarily involved ultrasound with or without fluoroscopy. A guidewire was used in 41.2% of procedures. A total of 290 catheters (286 Z-5 or Z-6) were used, achieving an overall BAS success rate of 96%. Complete procedural failure was associated with the use of the umbilical venous route (OR, 3.62; <em>P</em> <!-->=<!--> <!-->.001) and lower-volume catheters (OR, 7.01; <em>P</em> <!--><<!--> <!-->.001). The occurrence of significant complications (8%; OR, 9.33; <em>P</em> <!--><<!--> <!-->.001) was associated with complete procedural failure. For complex procedures, significant risk factors were the absence of fluoroscopy (OR, 3.32; <em>P</em> <!-->=<!--> <!-->.001), use of the umbilical venous route (OR, 2.28; <em>P</em> <!-->=<!--> <!-->.005), and lower-volume catheters (OR, 2.43; <em>P</em> <!-->=<!--> <!-->.03).</div></div><div><h3>Conclusions</h3><div>In the current era, BAS can be challenging, and significant complications and complete failures are not uncommon. The use of the umbilical venous route, low-volume BAS catheters, absence of fluoroscopy guidance, and the occurrence of complications negatively impact procedural outcomes.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 8","pages":"Pages 694-706"},"PeriodicalIF":5.9,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144714367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-25DOI: 10.1016/j.recesp.2025.02.024
Lidia Marcos-García , Albert Clarà , Sonia Pérez-Cabezón , Manuel Miralles-Hernández , Roberto Elosua , Alina Velescu
{"title":"Asociación entre la metilación del ADN en loci relacionados con el tabaco y mortalidad en pacientes con enfermedad arterial periférica","authors":"Lidia Marcos-García , Albert Clarà , Sonia Pérez-Cabezón , Manuel Miralles-Hernández , Roberto Elosua , Alina Velescu","doi":"10.1016/j.recesp.2025.02.024","DOIUrl":"10.1016/j.recesp.2025.02.024","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"79 1","pages":"Pages 80-82"},"PeriodicalIF":5.9,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145824126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-25DOI: 10.1016/j.recesp.2025.02.022
Miguel Morales-García , María Belén García-Ortega , José Pérez del Palacio , Eduardo Moreno-Escobar , Diego Segura-Rodríguez , Rocío García-Orta
{"title":"Identificación de nuevos biomarcadores en enfermedades de la aorta torácica ascendente mediante metabolómica basada en espectrometría de masas de alta resolución no dirigida","authors":"Miguel Morales-García , María Belén García-Ortega , José Pérez del Palacio , Eduardo Moreno-Escobar , Diego Segura-Rodríguez , Rocío García-Orta","doi":"10.1016/j.recesp.2025.02.022","DOIUrl":"10.1016/j.recesp.2025.02.022","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 12","pages":"Pages 1123-1124"},"PeriodicalIF":5.9,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-23DOI: 10.1016/j.recesp.2025.04.003
{"title":"¿Español o castellano?","authors":"","doi":"10.1016/j.recesp.2025.04.003","DOIUrl":"10.1016/j.recesp.2025.04.003","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 10","pages":"Page 837"},"PeriodicalIF":5.9,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145181353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-17DOI: 10.1016/j.recesp.2025.02.009
Luis E. Echeverría , Lyda Z. Rojas , Angie Yarlady Serrano-García , Daniel R. Botero , María Cantillo-Reines , Adriana M. Jurado , Karen Andrea García-Rueda , Ángela Torres-Bustamante , Diana Ivonne Cañón-Gómez , Carolina Idrovo-Turbay , Robinson Sánchez-García , Jaime Alberto Rodríguez , Sergio A. Gómez-Ochoa
Introduction and objectives
Although sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown benefits in acute decompensated heart failure (ADHF), the extrapolability of clinical trial results to general populations remains limited. This study evaluated the impact of early in-hospital SGLT2i prescription on ADHF outcomes in a real-world setting.
Methods
Prospective cohort study. Adults with ADHF from a third-level cardiovascular center were included. The primary analysis compared early SGLT2i (prescribed within 48 hours of admission) versus late SGLT2i (prescribed after 48 hours). A secondary analysis included patients not receiving in-hospital SGLT2i. The primary outcome was in-hospital mortality. Secondary outcomes included the length of hospital stay, 30-day improvement in the Minnesota Living with Heart Failure Questionnaire score, 30-day rehospitalization due to heart failure, and 30-day all-cause mortality.
Results
Of 2016 patients, early SGLT2i (≤ 48 h) was initiated in 1275 (63.2%) patients, late SGLT2i in 346 (17.2%), and 395 (19.6%) did not receive in-hospital SGLT2i. After multivariate adjustment, early versus late SGLT2i use was associated with decreased in-hospital mortality (RR, 0.37; 95%CI, 0.17-0.77) and reduced hospital stay (mean difference −5.70 days; 95%CI, −7.05 to −4.34). Similarly, early versus late or no in-hospital SGLT2i use was associated with decreased in-hospital mortality (RR, 0.25; 95%CI, 0.14-0.44), reduced hospital stay (mean difference −2.99 days; 95%CI, −4.05 to −1.92), and lower 30-day combined mortality/heart failure rehospitalization (RR, 0.72; 95%CI, 0.53-0.98).
Conclusions
Early in-hospital SGLT2i prescription was associated with improved cardiovascular outcomes in ADHF in a real-world setting.
{"title":"Impacto de la prescripción temprana de inhibidores de SGLT2 en los resultados de la insuficiencia cardiaca aguda descompensada: evidencia del mundo real","authors":"Luis E. Echeverría , Lyda Z. Rojas , Angie Yarlady Serrano-García , Daniel R. Botero , María Cantillo-Reines , Adriana M. Jurado , Karen Andrea García-Rueda , Ángela Torres-Bustamante , Diana Ivonne Cañón-Gómez , Carolina Idrovo-Turbay , Robinson Sánchez-García , Jaime Alberto Rodríguez , Sergio A. Gómez-Ochoa","doi":"10.1016/j.recesp.2025.02.009","DOIUrl":"10.1016/j.recesp.2025.02.009","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Although sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown benefits in acute decompensated heart failure (ADHF), the extrapolability of clinical trial results to general populations remains limited. This study evaluated the impact of early in-hospital SGLT2i prescription on ADHF outcomes in a real-world setting.</div></div><div><h3>Methods</h3><div>Prospective cohort study. Adults with ADHF from a third-level cardiovascular center were included. The primary analysis compared early SGLT2i (prescribed within 48<!--> <!-->hours of admission) versus late SGLT2i (prescribed after 48<!--> <!-->hours). A secondary analysis included patients not receiving in-hospital SGLT2i. The primary outcome was in-hospital mortality. Secondary outcomes included the length of hospital stay, 30-day improvement in the Minnesota Living with Heart Failure Questionnaire score, 30-day rehospitalization due to heart failure, and 30-day all-cause mortality.</div></div><div><h3>Results</h3><div>Of 2016 patients, early SGLT2i (≤<!--> <!-->48<!--> <!-->h) was initiated in 1275 (63.2%) patients, late SGLT2i in 346 (17.2%), and 395 (19.6%) did not receive in-hospital SGLT2i. After multivariate adjustment, early versus late SGLT2i use was associated with decreased in-hospital mortality (RR, 0.37; 95%CI, 0.17-0.77) and reduced hospital stay (mean difference −5.70 days; 95%CI, −7.05 to −4.34). Similarly, early versus late or no in-hospital SGLT2i use was associated with decreased in-hospital mortality (RR, 0.25; 95%CI, 0.14-0.44), reduced hospital stay (mean difference −2.99 days; 95%CI, −4.05 to −1.92), and lower 30-day combined mortality/heart failure rehospitalization (RR, 0.72; 95%CI, 0.53-0.98).</div></div><div><h3>Conclusions</h3><div>Early in-hospital SGLT2i prescription was associated with improved cardiovascular outcomes in ADHF in a real-world setting.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 9","pages":"Pages 780-788"},"PeriodicalIF":5.9,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144895204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号